PerkinElmer (NYSE:PKI) Updates Q4 2020 Pre-Market Earnings Guidance
PerkinElmer (NYSE:PKI) issued an update on its fourth quarter 2020
Pre-Market earnings guidance on Monday morning. The company provided earnings per share guidance of 3.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.79. The company issued revenue guidance of $1.337-1.337 billion, compared to the consensus revenue estimate of $1.18 billion.PerkinElmer also updated its Q4 guidance to at least $3.60 EPS.
PKI stock opened at $151.52 on Thursday. The company has a market cap of $16.97 billion, a price-to-earnings ratio of 57.61, a PEG ratio of 1.74 and a beta of 1.30. The company has a quick ratio of 0.91, a current ratio of 1.32 and a debt-to-equity ratio of 0.55. The business has a fifty day simple moving average of $143.51 and a 200-day simple moving average of $125.27. PerkinElmer has a 52 week low of $62.91 and a 52 week high of $162.70.
PerkinElmer (NYSE:PKI) last released its quarterly earnings data on Wednesday, October 28th. The medical research company reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.67. The business had revenue of $964.03 million during the quarter. PerkinElmer had a return on equity of 18.40% and a net margin of 9.87%. As a group, analysts expect that PerkinElmer will post 5.45 earnings per share for the current fiscal year.
Several analysts recently issued reports on the company. KeyCorp assumed coverage on PerkinElmer in a report on Monday, November 9th. They issued a sector weight rating and a $150.00 price target for the company. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their price target on PerkinElmer from $140.00 to $150.00 in a report on Friday, December 11th. Smith Barney Citigroup increased their price target on PerkinElmer from $140.00 to $150.00 in a report on Friday, December 11th. ValuEngine downgraded PerkinElmer from a hold rating to a sell rating in a report on Monday, November 2nd. Finally, The Goldman Sachs Group started coverage on shares of PerkinElmer in a research report on Wednesday, December 2nd. They issued a buy rating and a $160.00 price objective for the company. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company. PerkinElmer has a consensus rating of Hold and an average target price of $122.19.
In other PerkinElmer news, insider Andrew Okun sold 6,107 shares of the firm’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $140.14, for a total value of $855,834.98. Following the transaction, the insider now owns 16,417 shares of the company’s stock, valued at $2,300,678.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Daniel R. Tereau sold 4,094 shares of the firm’s stock in a transaction dated Monday, December 14th. The stock was sold at an average price of $146.68, for a total transaction of $600,507.92. Insiders have sold 20,837 shares of company stock worth $3,051,743 in the last ninety days. Corporate insiders own 0.62% of the company’s stock.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Featured Article: Stop Order Uses For Individual Investors
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.